Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen C Mathai

Showing results (61-70 of 217) with videos related to

Pageof 22
Sort By:
JHLT Open|August 14, 2025
Lung transplantation for connective tissue disease-related interstitial lung disease: Clinical outcomes compared to idiopathic pulmonary fibrosisSarah L Khan, Samuel J Minkove, Kevin J Psoter, et al.
Current Cardiology Reports|June 23, 2025
Innovating the Gold Standard: The Emerging Role of Echocardiographic Stress Testing in the Classification, Stratification, and Prognostication in Pulmonary Vascular DiseaseGarrett Goldin, Hoda Mombeini, Valentina Mercurio, et al.
American Journal of Respiratory and Critical Care Medicine|February 28, 2015
Vascular receptor autoantibodies in pulmonary arterial hypertensionKhalil I Bourji, Rubina M Khair, Rachel L Damico, et al.
Annals of the American Thoracic Society|July 1, 2026
Blood Pressure Change After Six-minute Walk Test Is an Independent Predictor of Clinical Worsening in Patients with Pulmonary HypertensionHai V Tran, Christopher Van Dreumel, Alison Schafer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 20, 2015
Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial HypertensionMatthew R Lammi, Stephen C Mathai, Lesley Ann Saketkoo, et al.
The European Respiratory Journal|September 29, 2018
Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction modelValentina Mercurio, Nermin Diab, Grace Peloquin, et al.
Annals of the American Thoracic Society|October 26, 2018
Discordance between Imaging Modalities in the Evaluation of Chronic Thromboembolic Pulmonary Hypertension: A Combined Experience from Two Academic Medical CentersDavid Furfaro, Javad Azadi, Traci Housten, et al.
Arthritis and Rheumatism|January 31, 2009
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung diseaseStephen C Mathai, Laura K Hummers, Hunter C Champion, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 4, 2021
Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational RegistriesDinesh Khanna, Carol Zhao, Rajan Saggar, et al.
Pulmonary Circulation|August 7, 2019
Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertensionCatherine E Simpson, Rachel L Damico, Laura Hummers, et al.
Pageof 22

Showing results (61-70 of 217) with videos related to

Sort By:
Pageof 22
JHLT Open|August 14, 2025
Lung transplantation for connective tissue disease-related interstitial lung disease: Clinical outcomes compared to idiopathic pulmonary fibrosisSarah L Khan, Samuel J Minkove, Kevin J Psoter, et al.
Current Cardiology Reports|June 23, 2025
Innovating the Gold Standard: The Emerging Role of Echocardiographic Stress Testing in the Classification, Stratification, and Prognostication in Pulmonary Vascular DiseaseGarrett Goldin, Hoda Mombeini, Valentina Mercurio, et al.
American Journal of Respiratory and Critical Care Medicine|February 28, 2015
Vascular receptor autoantibodies in pulmonary arterial hypertensionKhalil I Bourji, Rubina M Khair, Rachel L Damico, et al.
Annals of the American Thoracic Society|July 1, 2026
Blood Pressure Change After Six-minute Walk Test Is an Independent Predictor of Clinical Worsening in Patients with Pulmonary HypertensionHai V Tran, Christopher Van Dreumel, Alison Schafer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 20, 2015
Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial HypertensionMatthew R Lammi, Stephen C Mathai, Lesley Ann Saketkoo, et al.
The European Respiratory Journal|September 29, 2018
Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction modelValentina Mercurio, Nermin Diab, Grace Peloquin, et al.
Annals of the American Thoracic Society|October 26, 2018
Discordance between Imaging Modalities in the Evaluation of Chronic Thromboembolic Pulmonary Hypertension: A Combined Experience from Two Academic Medical CentersDavid Furfaro, Javad Azadi, Traci Housten, et al.
Arthritis and Rheumatism|January 31, 2009
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung diseaseStephen C Mathai, Laura K Hummers, Hunter C Champion, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 4, 2021
Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational RegistriesDinesh Khanna, Carol Zhao, Rajan Saggar, et al.
Pulmonary Circulation|August 7, 2019
Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertensionCatherine E Simpson, Rachel L Damico, Laura Hummers, et al.
Pageof 22